Zymeworks, Inc. (ZYME)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$28.74-7.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ZYME
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 12.0% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 72.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
ZYME — capital allocation — Creation of a Direct Financial Obligation or an Obligation under an Off-Balan…
Dated 2026-09-23
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Why it matters: The prior cost plan excluded the acquisition. Updated cost figures will show whether the larger business stays within its new plan.
Worry ifThe next financial outlook sets combined adjusted operating costs above the prior $300 million three-year plan. Or it reports rising costs without a new target.
Less concerning ifThe company gives a new combined-business cost plan and reports costs in line with that plan.
Why it matters: FDA approval would trigger a $250 million payment from Jazz. It could also lift royalty income from Ziihera sales.
Supportive ifFDA approves zanidatamab for first-line HER2-positive GEA. Jazz pays the $250 million milestone.
Worry ifFDA rejects the application or delays action, and the $250 million milestone is not paid.
Why it matters: Zymeworks hired MTS Healthcare to seek partners for ZW191. A deal could fund more work without relying only on company cash.
Supportive ifZymeworks names a partner for ZW191. Or, it reports signed terms for funding more development.
Worry ifA later company update reports no partner or funding deal, or says the search has ended.
Why it matters: The deal adds YUPELRI cash flow and other royalty assets. The first results will show how much the combined business brings in.
Supportive ifA report after the deal closes shows the combined business has positive cash flow. YUPELRI is near the stated $60 million annual run rate.
Worry ifA report after close shows negative cash flow for the combined business. Or, YUPELRI cash flow is below the stated run rate.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $412 loss on $10,000 · 4.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,363 loss on $10,000 · 23.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The payment depends on the next trial step. A start would mark progress for a new partnered program.
Supportive ifRoche starts the ZW209 Phase 1b trial and Zymeworks reports receipt of the $40 million payment.
Worry ifThe Phase 1b trial has not started and the payment remains unpaid in a later company update.